LOS ANGELES, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming October 27, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) securities between May 7, 2025 and August 5, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR LIFEMD INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOU ...

Core Viewpoint - Schubert Jonckheer & Kolbe LLP is investigating potential legal claims against Hayward Holdings, Inc. regarding misleading sales practices and inventory levels [1][2] Group 1: Legal Investigation - The firm is looking into allegations that Hayward misled investors about its sales practices and inventory levels [1][2] - A U.S. District Court ruling allows a securities fraud lawsuit against Hayward and its executives to proceed [1] - The lawsuit claims that Hayward engaged in "channel stuffing" between October 2021 and July 2022, artificially inflating sales figures [1] Group 2: Impact on Company Performance - The alleged practices led to an undisclosed inventory glut, negatively affecting future sales [1] - Following the revelation of these practices in July 2022, Hayward's stock price fell by 18% [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after disappointing trial results for Pemvidutide, urging affected investors to consider their legal options [2][4][5]. Group 1: Company Overview - Altimmune, Inc. is a biopharmaceutical company whose stock is traded on NASDAQ under the ticker symbol ALT [2]. - The company recently announced topline results from the IMPACT Phase 2b MASH trial, which did not meet statistical significance for its primary endpoint [4]. Group 2: Legal Actions and Investor Impact - A federal securities class action has been filed against Altimmune, with a deadline of October 6, 2025, for investors to seek the role of lead plaintiff [2][6]. - Following the announcement of the trial results, Altimmune's stock price plummeted from $7.71 per share to $3.61 per share, marking a decline of 53.2% in one day [5]. - The firm encourages any individuals with information regarding Altimmune's conduct to come forward, including whistleblowers and former employees [7].

Core Viewpoint - The Lockheed Martin Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and lack of effective internal controls during the specified class period [1][3]. Group 1: Allegations and Financial Impact - The lawsuit alleges that Lockheed Martin made false statements regarding its internal controls and ability to meet contract commitments, which led to significant financial losses [3]. - On October 22, 2024, Lockheed Martin announced an $80 million loss on a classified program, causing a stock price drop of over 6% [4]. - On January 28, 2025, the company reported pre-tax losses of $1.7 billion related to classified programs, resulting in a stock price decline of more than 9% [5]. - On July 22, 2025, Lockheed Martin disclosed an additional $1.6 billion in pre-tax losses, including $950 million from its Aeronautics Classified program, leading to a nearly 11% drop in stock price [6]. Group 2: Class Action Process - Investors who purchased Lockheed Martin securities during the class period can seek appointment as lead plaintiff in the lawsuit, representing the interests of the class [7]. - The lead plaintiff can select a law firm to litigate the case and does not need to be the lead plaintiff to share in any potential recovery [7]. Group 3: About the Law Firm - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8].

Core Viewpoint - RxSight, Inc. is facing a class action lawsuit due to significant declines in sales and revenue, leading to a substantial drop in stock price following the release of disappointing financial results for Q2 2025 [2][3]. Financial Performance - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in LDD sales, LAL utilization, and overall revenue [2]. - The company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [2]. - Following the announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, with unusually heavy trading volume [2]. Lawsuit Details - The class action lawsuit alleges that during the Class Period, RxSight's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [3]. - Specific allegations include: (1) the company faced "adoption challenges" leading to declines in sales and utilization; (2) overstated demand for RxSight's products; (3) unlikelihood of meeting previously issued financial guidance for fiscal year 2025; (4) positive statements about the company's business were materially misleading [3]. Legal Actions - Investors who purchased or acquired RxSight securities during the Class Period can file a lead plaintiff motion by September 22, 2025 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vestis Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's growth and business strategies [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $75,000 in Vestis between May 2, 2024, and May 6, 2025, to discuss their legal rights [1]. - There is an August 8, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Vestis [2]. - The complaint alleges that Vestis and its executives concealed material adverse facts regarding the company's ability to grow its business and execute strategic initiatives [4]. Group 2: Financial Performance and Stock Impact - On May 7, 2025, Vestis announced disappointing financial results for Q2 2025, withdrew its revenue guidance for the full fiscal year, and provided lower-than-expected guidance for Q3 2025 [5]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating challenges in customer retention and growth [5]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [5].